Fort Sheridan Advisors LLC Sells 352 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Fort Sheridan Advisors LLC decreased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 14.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,076 shares of the pharmaceutical company’s stock after selling 352 shares during the quarter. Fort Sheridan Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $924,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in VRTX. Activest Wealth Management bought a new position in Vertex Pharmaceuticals during the first quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares in the last quarter. Access Investment Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $27,000. Flaharty Asset Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $32,000. Finally, Legacy Investment Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the second quarter valued at $29,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other news, Chairman Jeffrey M. Leiden sold 53,604 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $440.72, for a total value of $23,624,354.88. Following the completion of the sale, the chairman directly owned 24,026 shares in the company, valued at approximately $10,588,738.72. This trade represents a 69.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Down 1.8%

NASDAQ VRTX opened at $425.60 on Tuesday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68. The company has a 50 day moving average of $416.43 and a 200-day moving average of $424.97. The firm has a market cap of $107.98 billion, a price-to-earnings ratio of 30.42 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the company earned $4.38 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analysts Set New Price Targets

VRTX has been the topic of several analyst reports. Guggenheim lowered their price target on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Morgan Stanley lowered their target price on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Truist Financial set a $490.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 8th. Finally, HC Wainwright dropped their target price on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating for the company in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $491.95.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.